Published February 28, 2023

According to IMARC Group's latest research report, titled "Idiopathic Pulmonary Fibrosis (IPF) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2032", offers a comprehensive analysis of the industry, which comprises insights on idiopathic pulmonary fibrosis (IPF) market size.

Idiopathic pulmonary fibrosis (IPF) represents an irreversible and progressive fibrosing interstitial pneumonia that directly impacts the functioning of the lungs. It is usually characterized by the formation of scar tissue within the lungs that starts at the edges and progresses towards the center, thereby causing insufficient delivery of oxygen to the body parts and difficulties in breathing. IPF is diagnosed via lung biopsies, pulmonary function tests, chest imaging studies, antibody tests, etc. In addition to this, some of the common treatment methods for idiopathic pulmonary fibrosis include nintedanib and pirfenidone-based drugs that assist in lung functioning and minimizing the risk of acute respiratory deterioration. They are also provided, along with oxygen therapy and palliative care, which enhance the chances of recovery and offer comfort to patients.

Get Free Sample Copy of Report at –

Time Period of the Study:

  • Base Year: 2021
  • Historical Period: 2017-2021
  • Market Forecast: 2022-2032

Idiopathic Pulmonary Fibrosis (IPF) Market Growth Factors:

The widespread adoption of nicotine products, such as cigarettes, and changing lifestyle patterns of individuals are primarily driving the idiopathic pulmonary fibrosis treatment market. Additionally, the expanding geriatric population and the growing prevalence of lung disorders are further catalyzing the market growth. Besides this, the rising consumer consciousness towards effective management strategies of IPF is acting as another significant growth-inducing factor. Moreover, the increasing investments by key market players in the development and commercialization of novel drugs are positively influencing the market. Apart from this, continuous advancements in the idiopathic pulmonary fibrosis diagnostic and treatment methods are also bolstering the market growth. Furthermore, extensive R&D activities and several improvements in the healthcare infrastructures are expected to fuel the idiopathic pulmonary fibrosis treatment market over the forecasted period.

Explore Full Report:

Key Market Segmentation:

Idiopathic Pulmonary Fibrosis: In-Market and Pipeline Drugs

  • In-Market Idiopathic Pulmonary Fibrosis Drugs
    • Drug Overview
    • Mechanism of Action
    • Regulatory Status
    • Clinical Trial Results
    • Drug Uptake and Market Performance
  • Late-Stage Pipeline Idiopathic Pulmonary Fibrosis Drugs
    • Drug Overview
    • Mechanism of Action
    • Regulatory Status
    • Clinical Trial Results
    • Regulatory Status

Countries Covered:

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Epidemiology Insights:

  • What is the size of the Idiopathic Pulmonary Fibrosis patient pool (2017-2021) across the seven major markets?
  • What would be the forecasted patient pool (2022-2032) of Idiopathic Pulmonary Fibrosis across the seven major markets?
  • What are the key factors driving the epidemiological trend of Idiopathic Pulmonary Fibrosis?
  • What will be the growth rate of Idiopathic Pulmonary Fibrosis patients across the seven major markets?

Browse the Latest Research Report:

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact us:


134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

Source link